October 3, 2025
1 min read

Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate

The initial part of the up-to-$339 million funding will largely be used to establish U.S. manufacturing for the non-vaccine flu preventive candidate, with additional options tied to further clinical studies, Cidara said.

Leave a Reply

Your email address will not be published.

Previous Story

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Next Story

FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing

Previous Story

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Next Story

FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop